Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, has been elected a Fellow of the Royal Society

This accolade is one of the highest honours in science and is given to individuals who have made a "substantial contribution to the improvement of natural knowledge, including mathematics, engineering science and medical science". The award recognises his unique contributions to understanding human immunity, his ground-breaking research on vaccines to prevent life-threatening childhood diseases like typhoid, meningitis and pneumonia, and his invaluable leadership in the development of vaccines for outbreaks of influenza, Ebola, and COVID-19 among others.

Professor Sir Andrew Pollard said: "It is a huge honour to be elected as a Fellow of the Royal Society to join these most distinguished scientists of our time, standing on the shoulders of those past Fellows who changed our world over the past three and a half centuries.  I am more than aware that this is not about me but recognition of the large team of brilliant researchers at the Oxford Vaccine Group and our global collaborators who have made extraordinary contributions to improving lives through immunisation ."

The Royal Society, established over 360 years ago, is the world's oldest scientific academy in continuous existence, dedicated to promoting excellence in science.  

Similar stories

Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Lymph Node Research UK launches with national network of ten specialist research centres

Oxford, 16 June 2026: A new £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease has launched, bringing together ten specialist centres across the country.

Similar stories

Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Lymph Node Research UK launches with national network of ten specialist research centres

Oxford, 16 June 2026: A new £1.7 million UK-wide research network dedicated to unlocking the role of lymph nodes in infection, immunity and inflammatory disease has launched, bringing together ten specialist centres across the country.